Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Scientific Advisory Board

Elizabeth P. Rakoczy, Ph.D.
Chair

Dr. Rakoczy is the Winthrop Professor of Molecular Ophthalmology at the Lions Eye Institute, University of Western Australia, and has pioneered work in gene therapy for ocular neovascular disease.


Jean E. Bennett, M.D., Ph.D.

Dr. Bennett is the F.M. Kirby Professor of Ophthalmology at the University of Pennsylvania and is a renowned expert in gene therapy, animal models, and translational medicine in retinal disease.


Estuardo Aguilar-Cordova, M.D., Ph.D.

Dr. Aguilar-Cordova is the Chief Executive Officer, Advantagene, and a recognized expert in regulatory affairs and product development in both academic and biotechnology settings.


Thomas W. Chalberg, Jr., PhD

Dr. Chalberg is a founder of Avalanche Biotechnologies and brings many years of experience in ophthalmology research and development and commercialization to the Board.


Mitchell H. Finer, Ph.D.

Dr. Finer is a founder and Distinguished Research Fellow of Avalanche Biotechnologies. Dr. Finer was most recently the Chief Scientific Officer of bluebird bio. He has over 25 years of experience in biotechnology product development.


Daniel V. Palanker, Ph.D.

Dr. Palanker is the Associate Professor in the Department of Ophthalmology and in Hansen Experimental Physics Laboratory at Stanford University. He is an expert in ophthalmic lasers and in interactions of pulsed electric field and light with biological cells and tissues.

Avalanche Biotechnologies Announces Leadership Transition

July 23, 2015

MENLO PARK, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL) announced today that Thomas W. Chalberg, Jr., Ph.D., has resigned as chief executive officer (CEO) and president and as a member of the Board of Directors, effective July 23, 2015.

Read More

Read All Avalanche News